First and foremost, if there was any good time to acquire The Medicines Co., now would be it. The company is on the verge of a submission of an application to the FDA for the reduction of LDL cholesterol.
At the moment, the standard of care for these patients are treatments known as statins. However, Inclisirin works very differently and may very well become the standard of care for the reduction of bad cholesterol in high risk patients.
As such, if a company like Novartis were interested in a takeover, now would be the time to act. After all, if MDCO does receive FDA approval, the price of the company would skyrocket. So, any suitor that believed that approval would take place would need to act before this happens.
Moreover, Novartis is a perfect fit for MDCO. The company has multiple products in the cardiovascular health space, and is in the process of researching others. So, acquiring The Medicines Company would only serve to enhance the company’s lineup of products.
While there can be no assurance that a deal will take place, this is one to watch closely as the likelihood that the chatter surrounds a real possibility of a takeover.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Don’t Miss The Next Big Story!
Join our free mailing list below to receive real-time news alerts!